CIN85 Inhibitors

BMS-536924 functions as a dual inhibitor targeting both the IGF-1R and IR receptors, thereby disrupting the downstream signaling pathways associated with CIN85. This compound interferes with the intricate network of interactions between CIN85 and the IGF-1R/IR pathways, leading to the inhibition of CIN85's cellular functions.

NSC 697923 inhibits CIN85 by targeting the Src homology 3 (SH3) domains crucial for protein-protein interactions. By disrupting the binding sites essential for CIN85 engagement with other signaling molecules, NSC 697923 effectively interferes with the assembly of protein complexes involving CIN85, leading to the modulation of its cellular functions.

LAQ824 (Dacinostat), a histone deacetylase inhibitor, indirectly inhibits CIN85 by influencing epigenetic modifications. Through the modulation of gene expression patterns, Dacinostat disrupts the balance of proteins involved in the pathways associated with CIN85, resulting in the attenuation of its cellular functions.

Tyrphostin AG 1478 acts as a selective EGFR inhibitor, disrupting the EGFR-mediated signaling cascades involving CIN85. By inhibiting EGFR, this compound indirectly interferes with the activation and functions of CIN85, highlighting a regulatory link between EGFR and CIN85 in cellular processes.

PD 98059 inhibits MEK1, a component of the MAPK pathway. By disrupting this critical node in the signaling network, PD 98059 indirectly modulates the downstream effects on CIN85, influencing its functions within the intricate MAPK pathway.

Wortmannin inhibits PI3K, a key player in the PI3K/Akt signaling pathway. By disrupting PI3K activity, Wortmannin indirectly influences the downstream signaling events involving CIN85, shedding light on the intricate crosstalk between PI3K/Akt and CIN85-mediated cellular functions.

C646 acts as a selective inhibitor of the histone acetyltransferase p300, impacting epigenetic regulation. By modulating the acetylation patterns of histones, C646 indirectly influences the expression of genes involved in pathways associated with CIN85, providing an indirect means of inhibiting CIN85 functions through epigenetic modifications.

Sorafenib functions as a multi-kinase inhibitor targeting Raf kinases among others. By disrupting the Raf/MEK/ERK signaling cascade, Sorafenib indirectly affects the downstream events involving CIN85, emphasizing the intricate interplay between kinase pathways and CIN85-mediated cellular processes.

Triciribine inhibits Akt, a pivotal kinase in the PI3K/Akt signaling pathway. By disrupting Akt activity, Triciribine indirectly modulates the downstream signaling cascades involving CIN85, revealing the interconnectedness of the PI3K/Akt pathway with CIN85-mediated cellular functions.

PP2 is a selective inhibitor of Src family kinases, disrupting their role in various signaling pathways. By inhibiting Src family kinases, PP2 indirectly influences the cellular processes governed by CIN85, revealing the intricate regulatory mechanisms associated with the Src family kinases and their impact on CIN85 functions.